Table 1.
Patient characteristics.
Table 2.
Plasma concentrations of cytokines in control, CD, and DCM groups expressed as mean ± standard error of the mean (SEM).
Table 3.
Correlation of 21 different cytokines with echocardiographic parameters in CD (NYHA I-IV) and DCM (NYHA I-IV) patients.
Fig 1.
A. Plasma concentration of MIF in controls (n = 25); in patients with CD distributed in asymptomatic (0) (n = 46), NYHA classes I-II (n = 24), and NYHA classes III-IV (n = 23); and in patients with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± SEM. * p < 0.05 vs control. B. Plasma concentration of CXCL12 in controls (n = 21); in patients with CD distributed in asymptomatic (0) (n = 44), NYHA classes I-II (n = 25), and NYHA classes III-IV (n = 23); and in patients with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± SEM. * p < 0.05 vs control.
Fig 2.
Receiver operating characteristic (ROC) and Kaplan-Meier curves (MIF).
A. ROC curve was used to define cut-off value for MIF with best sensitivity and specificity based on CD patients in NYHA classes I-IV (Sensitivity: 64.00%; Specificity: 52.08%). The cut-off value was calculated to be 152.7 pg/mL. B, C. Kaplan-Meier survival curves were generated to compare percent survival in CD (B) and DCM (C) patients with MIF higher or lower than cut-off value (cut-off = 152.7 pg/mL); * p < 0.05.
Fig 3.
ROC and Kaplan-Meier curves (CXCL12).
A. ROC curve was used to define cut-off value for CXCL12 with best sensitivity and specificity based on CD patients in NYHA classes I-IV (Sensitivity: 85.71%; Specificity: 45.83%). The cut-off value was calculated to be 229.8 pg/mL. B, C. Kaplan-Meier survival curves were generated to compare percent survival in CD (B) and DCM (C) patients with CXCL12 higher or lower than cut-off value (cut-off = 229.8 pg/mL); ** p < 0.01. Statistical analysis were carried out by log-rank test.